GoodRx account plan
Healthcare cost savings app
At a glance
GoodRx (Nasdaq: GDRX) is a US prescription savings platform with $796.9 million of FY2025 revenue, shifting toward pharma and subscriptions.
GoodRx Holdings, Inc. runs a consumer-focused digital healthcare platform in the United States: a prescription price-comparison marketplace, subscriptions and Pharma Direct, which sells advertising and consumer affordability programs to drug manufacturers. All revenue is generated in the United States. For FY2025 (calendar year) it reported revenue of $796.9 million, net income of $30.4 million and Adjusted EBITDA of $270.5 million, with 697 full-time employees at December 31, 2025. It is listed on Nasdaq under GDRX and is a "controlled company": the parties to its stockholders agreement, which include Silver Lake, Francisco Partners and Idea Men, LLC, held about 93.8% of voting power at December 31, 2025. Wendy Barnes is Chief Executive Officer.
Business units
Prescription transactions
68% of FY2025 revenue ($544,001 thousand)The prescription marketplace: free GoodRx codes that give consumers PBM-negotiated or direct-contract prices at pharmacies. Revenue fell 6% in FY2025 on a 14% decrease in Monthly Active Consumers, and fell 26% year over year in Q2 2026 as originally filed.
Pharma Direct
19% of FY2025 revenue ($151,380 thousand)Formerly Pharma Manufacturer Solutions. Sells advertising and integrated affordability programs, including consumer direct pricing for branded drugs, to pharma manufacturers. Revenue rose 41% in FY2025 and was the fastest-growing line; GLP-1 access programs are a major driver.
Subscriptions
11% of FY2025 revenue ($83,786 thousand)Gold, RxSmartSaver+, condition-specific programs for erectile dysfunction, weight management and hair loss, and GoodRx Companion, launched in May 2026. Subscription plans were 764 thousand at June 30, 2026 against 674 thousand at December 31, 2025.
Other revenue
2% of FY2025 revenue ($17,686 thousand)A small residual line that the 10-K does not describe further.
Strategic priorities
- Scale Pharma Direct
- The company wants more manufacturers, more brands per manufacturer and more solutions per manufacturer. On the Q2 2026 call it counted more than 135 consumer direct pricing programs and raised its 2026 Pharma Direct growth expectation to more than 70%.
- Make subscriptions the primary consumer offer
- GoodRx Companion is now the primary subscription offering, at $14.99 per month or $9.99 per month on an annual plan, with 200 free generic medications. Subscriptions become the primary call to action on the homepage and price pages.
- Direct contracts with retail pharmacies
- The company has direct contracts with 9 of the top 10 retail pharmacies and had 6 of the top 10 live on its e-commerce platform at the end of 2025. E-commerce is live at nearly 6,000 pharmacies as of the Q2 2026 call.
- Employer Direct
- A platform that pairs employers' existing benefits with integrated cash pricing, starting with GLP-1 medications. Partners are expected to go live in Q4 and into Q1.
- 2026 guidance (raised in August)
- Full-year 2026 revenue of $790 million to $805 million and Adjusted EBITDA of $240 million to $250 million, with a return to year-over-year revenue growth expected earlier than previously anticipated. These figures were given before the later restatement of Q1 and Q2 2026.
- AI in the operating model
- Management is hiring talent and investing to embed AI in how it builds and scales the platform, aiming to speed product delivery and support operating leverage.
Latest results
For the quarter ended June 30, 2026, as originally filed on August 5, 2026, revenue was $200.4 million against $203.1 million a year earlier, and Adjusted EBITDA was $63.7 million (31.8% margin) against $69.4 million. Pharma Direct revenue was $61,628 thousand (up 76%), subscription revenue $28,514 thousand (up 39%) and prescription transactions revenue $106,390 thousand (down 26%). Monthly Active Consumers were 5.0 million against 5.7 million in Q2 2025. On October 27, 2026 the Audit and Risk Committee concluded that the Q1 and Q2 2026 financial statements should no longer be relied upon because Pharma Direct revenue was understated. Preliminary restated total revenue was $222,684 thousand for Q2 2026 and $424,190 thousand for the six months, and the amounts remain subject to change.
Investments and deals
- Acquisitions
- VCRx, a prescription savings business, for $30.0 million in cash on January 13, 2025, and ScriptDrop, a prescription delivery technology platform, for $13.4 million in cash on October 16, 2025.
- Subscription and Pharma Direct spending
- The company says it is directing more product and marketing investment toward subscriptions and Pharma Direct. Its customer acquisition costs for new subscribers are described as below industry benchmarks, so it plans to increase brand and performance marketing where unit economics are strong.
- Capital position
- Cash was $296.1 million at June 30, 2026, with $80.4 million available under an $88.0 million revolver. A term loan of $495.0 million of principal was outstanding at December 31, 2025, due July 2029.
Challenges and risks
- Falling prescription transactions
- Revenue in this line fell 6% in FY2025 and 26% in Q2 2026 as originally filed, with Monthly Active Consumers down on store closures, the Rite Aid bankruptcy and a volume reduction in one integrated savings program.
- Lower unit economics
- Management describes a deliberate reduction of fees negotiated with retail and PBM partners for longer-term durability, a headwind in the mid-single digits as a percentage of consolidated revenue.
- Restatement and internal controls
- The company expects to file amended Forms 10-Q for the first two quarters of 2026 and currently expects to report one or more material weaknesses in internal control over financial reporting.
- Dependence on PBMs and pharmacy chains
- The three largest PBM customers accounted for 22% of 2025 revenue. The 10-K flags consolidation among PBMs and national pharmacy chains as a risk to pricing.
- Policy uncertainty around TrumpRx
- GoodRx is an integration partner for manufacturers' cash prices on TrumpRx, but the 10-K says the impact of TrumpRx on its business is unclear and "may be significant".
What leadership says
“GoodRx has become one of the leading consumer access channels for GLP-1 medications in the U.S.”
“While we are not discontinuing Gold, Companion is now our primary subscription offering with a broader nationwide pharmacy network, richer benefits and consistently lower prices.”
“Brands used to be a loser at retail, and we are ensuring that it no longer is.”
Where a supplier can help
- Finance and revenue-recognition tooling
- The restatement of Q1 and Q2 2026 for understated Pharma Direct revenue, and the expected material weaknesses, point to demand for revenue recognition, close and controls automation, and audit support.
- Subscription growth and retention
- With Companion as the primary subscription offering and subscription plans at 764 thousand, there is room for suppliers in acquisition funnels, billing, retention and reactivation, tied to the shift of marketing toward subscriptions.
- Pharma Direct and Employer Direct delivery
- Scaling more than 135 consumer direct pricing programs and a new employer pipeline creates needs in program operations, manufacturer reporting and benefits integration.
- AI for workflow and product delivery
- Management says it is hiring and investing to embed AI into the operating model, which opens room for tools that reduce manual work in engineering, operations and support.
- Pharmacy e-commerce and delivery
- E-commerce live at nearly 6,000 pharmacies and the ScriptDrop acquisition show active investment in digital fulfilment and delivery for retail partners.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like GoodRx?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- GoodRx Holdings, Inc. Form 10-K for the fiscal year ended December 31, 2025
- GoodRx Holdings, Inc. (Nasdaq: GDRX) runs a consumer-focused digital healthcare platform in the United States: a prescription price-comparison marketplace, subscriptions and, since 2025, "Pharma Direct" (formerly Pharma Manufacturer Solutions) for drug makers. It reports one operating segment and all revenue is generated in the United States.
- FY2025 (calendar year): revenue $796.9 million (+1% from $792.3 million), net income $30.4 million (3.8% margin), Adjusted EBITDA $270.5 million (33.9% margin); 697 full-time employees at December 31, 2025.
- Revenue mix FY2025: prescription transactions $544,001 thousand (68%, down 6%), Pharma Direct $151,380 thousand (19%, up 41%), subscriptions $83,786 thousand (11%, down 3%), other $17,686 thousand (2%).
- Monthly Active Consumers fell to 5.3 million in Q4 2025 from 6.6 million in Q4 2024 after the Rite Aid bankruptcy, store closures and a volume reduction in one integrated savings program (estimated $35.0 million to $40.0 million hit to prescription transactions revenue in 2025). Subscription plans: 674 thousand.
- Strategy: keep the prescription marketplace foundational while investing in Pharma Direct, subscriptions (Gold, RxSmartSaver+, condition-specific programs for erectile dysfunction, weight management and hair loss) and the new Employer Direct platform; deepen retail pharmacy relationships; the company expects "near-term impact" on prescription transactions unit economics in 2026.
- GoodRx is a "key integration partner" for manufacturers' discounted cash prices on TrumpRx.gov (launched February 2026); the 10-K says the impact of TrumpRx is unclear and "may be significant".
- Concentration: the three largest PBM customers were 22% of 2025 revenue (27% in 2024, 32% in 2023). Parties to the stockholders agreement (Silver Lake, Francisco Partners, Idea Men, LLC and others) held about 93.8% of voting power at December 31, 2025, so GoodRx is a Nasdaq "controlled company".
- Balance sheet: $261.8 million cash, $495.0 million term loan principal due July 2029, $88.0 million revolver undrawn.
- GoodRx Holdings, Inc. Form 10-Q for the quarter ended June 30, 2026
- Q2 2026 (quarter ended June 30, 2026), as originally filed on August 5, 2026: revenue $200.4 million against $203.1 million a year earlier; net income $8.5 million (4.3% margin) against $12.8 million (6.3%); Adjusted EBITDA $63.7 million (31.8% margin) against $69.4 million (34.2%).
- Mix shift: Pharma Direct revenue $61,628 thousand (31% of revenue, up 76%), subscription revenue $28,514 thousand (14%, up 39%), prescription transactions $106,390 thousand (53%, down 26%).
- Monthly Active Consumers 5.0 million (5.7 million in Q2 2025); subscription plans 764 thousand (668 thousand a year earlier). Prescription transactions fell on fewer consumers, "lower unit economics" and a deliberate shift of product and marketing investment to subscriptions.
- Six months ended June 30, 2026: revenue $394.4 million against $406.0 million; net income $9.7 million against $23.9 million; Adjusted EBITDA $122.0 million (30.9% margin) against $139.2 million (34.3%).
- Launches: GoodRx Companion (monthly plans May 2026, annual plans July 2026), Employer Direct (announced Q1 2026), and consumer direct pricing for Lipitor, Celebrex, Viagra and Norvasc. TrumpRx expanded in May 2026 to more than 600 generic medications with GoodRx offers integrated.
- Balance sheet: cash $296.1 million, $80.4 million available on the revolver; operating cash flow $92,670 thousand in six months against $58,993 thousand.
- Caveat added by the curator, not part of this filing: the company later withdrew reliance on these quarterly figures; see the separate Form 8-K document.
- GoodRx Holdings, Inc. Form 8-K, Item 4.02: non-reliance on Q1 and Q2 2026 financial statements
- On October 27, 2026 the Audit and Risk Committee of GoodRx's Board concluded, after discussion with management and the auditor KPMG LLP, that the condensed financial statements for the quarters ended March 31, 2026 and June 30, 2026 should no longer be relied upon.
- Cause: an understatement of Pharma Direct revenue (a portion of revenue was not recognized in each period when it should have been under ASC 606), tied to an ongoing Audit and Risk Committee review of revenue recognition for certain Pharma Direct transactions.
- Preliminary effect, three months ended March 31, 2026: Pharma Direct revenue $52,230 thousand as reported, plus $7,500 thousand, restated $59,730 thousand; total revenue $194,006 thousand, restated $201,506 thousand; net income $1,169 thousand, restated $4,960 thousand.
- Preliminary effect, three months ended June 30, 2026: Pharma Direct revenue $61,628 thousand as reported, plus $22,273 thousand, restated $83,901 thousand; total revenue $200,411 thousand, restated $222,684 thousand; operating income $23,632 thousand, restated $38,509 thousand; net income $8,536 thousand, restated $19,592 thousand.
- Preliminary effect, six months ended June 30, 2026: total revenue $394,417 thousand, restated $424,190 thousand; operating income $37,641 thousand, restated $57,828 thousand; net income $9,705 thousand, restated $24,552 thousand.
- The company has not identified any impact on periods before fiscal year 2026; it expects to file amended Forms 10-Q "as soon as practicable" and currently expects to report one or more material weaknesses in internal control over financial reporting as of the end of each affected period.
- The amounts are preliminary and subject to change. The 8-K is signed by Chief Executive Officer and President Wendy Barnes and is dated November 2, 2026.
- GoodRx (GDRX) Q4 2025 earnings call transcript
- Fourth-quarter and full-year 2025 call (February 26, 2026), CEO Wendy Barnes with CFO Chris McGinnis and Chief Commercial Officer and President of Pharma Direct Laura Jensen: FY2025 revenue $796.9 million (up 1%), Adjusted EBITDA $270.5 million (up 4%); Q4 revenue $194.8 million, Adjusted EBITDA $65 million.
- Mix: prescription transactions revenue down 6% to $544 million; subscription revenue down 3% to $83.8 million; Pharma Direct (previously Pharma Manufacturer Solutions) up 41% to $151.4 million.
- Pharma Direct is positioned as "a key growth engine"; more than 100 brand self-pay programs live, many integrated into TrumpRx, including over 30 of Pfizer's essential brand medications; the company says it accounted for nearly 20% of Wegovy pill self-pay fills in one January week.
- 2026 guidance: revenue $750 million-$780 million, Adjusted EBITDA of at least $230 million, Pharma Direct growth of at least 30%. Management calls this a deliberate reset: lower fees negotiated with retail partners for longer-term durability are a mid-single-digit headwind as a percentage of consolidated revenue.
- Retail: direct contracts with 9 of the top 10 retail pharmacies; 6 of the top 10 live on the e-commerce platform at year end; order volume up 83% quarter over quarter.
- Subscriptions: condition-specific programs (erectile dysfunction, hair loss, weight loss) exceeded expectations; Employer Direct launched with GLP-1 focus.
- Capital: $261.8 million cash; 48.9 million shares repurchased at an average $4.45, totaling $217.4 million in 2025.
- Monthly active consumers fell 14% in 2025; management expects them to flatten sequentially from Q4 2025 through Q4 2026 (exit rate of 2025 was 5.3 million, modeled at about 5.2 million at year end 2026).
- GoodRx (GDRX) Q2 2026 earnings call transcript
- Second-quarter 2026 call (August 6, 2026), CEO Wendy Barnes with newly appointed CFO Justin Fengler (also Chief Strategy and Operations Officer); figures are as presented on the call. Revenue $200.4 million, Adjusted EBITDA $63.7 million (31.8% margin).
- Pharma Direct revenue $61.6 million, up 76% year over year and 18% quarter over quarter, 31% of revenue; more than 135 consumer direct pricing programs, adding Jardiance, Nurtec, Otezla and Rapaflo. Subscription revenue $28.5 million, up 39%; subscription plans up 14%. Prescription transactions revenue $106.4 million.
- Monthly active consumers 5 million, down 12% year over year; management expects continued moderation as users move to subscriptions.
- GoodRx Companion launched in May at $14.99 per month or $9.99 per month on an annual plan, with 200 free generic medications; it is now the primary subscription offering, though Gold is not discontinued.
- Guidance raised: full-year 2026 revenue $790 million to $805 million, Adjusted EBITDA $240 million to $250 million, Pharma Direct revenue growth now more than 70% (was 50% when the range was raised). Management expects a return to year-over-year revenue growth this year, earlier than previously anticipated.
- Employer Direct pipeline with partners expected to go live in Q4 and into Q1; AI embedded into the operating model; Medicare bridge program for GLP-1s (July 1 to the end of 2027) expected to have limited reach.
- Capital allocation: no buybacks in the quarter; priority is investing in the business, with M&A opportunistic.
- Chris McGinnis transitioned from CFO the day before the call.
Questions about GoodRx
What does GoodRx do?
GoodRx runs a US digital healthcare platform where consumers find lower prescription prices and use free GoodRx codes at pharmacies. It also sells subscriptions to consumers and Pharma Direct affordability and advertising programs to drug manufacturers.
How much revenue does GoodRx make?
GoodRx reported FY2025 revenue of $796.9 million, up 1% from $792.3 million, with Adjusted EBITDA of $270.5 million (33.9% margin). Prescription transactions were 68% of revenue, Pharma Direct 19% and subscriptions 11%.
How many employees does GoodRx have?
GoodRx had 697 full-time employees at December 31, 2025, according to its 10-K.
Who owns and leads GoodRx?
Wendy Barnes is Chief Executive Officer. Silver Lake, Francisco Partners and Idea Men, LLC are parties to a stockholders agreement that held about 93.8% of voting power at December 31, 2025, making GoodRx a controlled company.
What is GoodRx's strategy?
It keeps the prescription marketplace as its foundation while investing in Pharma Direct, subscriptions such as GoodRx Companion, deeper retail pharmacy relationships and Employer Direct. It expects near-term pressure on prescription transactions revenue in 2026.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-19)